Anthropic and OpenEvidence bring free clinical AI to doctors in ~100 low- and middle-income countries; OpenEvidence raises $250M at $15B
Confirmed
Status
- Claim
Confirmed
- Our reporting
- High confidence
- Importance
- 2 of 5
- Last verified
- 30 September 2026
Your AI and this story
- GPT-6.2 Astra114 days after its cutoff
- Claude Opus 5.584 days after its cutoff
- Gemini 4 Hydrogen175 days after its cutoff
- Grok 4.7114 days after its cutoff
None of these four assistants can know about it. The closest, Claude Opus 5.5, stops 84 days before it.
Key facts
- Partnership: OpenEvidence adapts a free version to local disease patterns, diagnostics and treatments (usable by smartphone); Anthropic provides back-end model capacity, Claude credits, dedicated engineers and funding for an LMIC access team (Reuters, Fierce Healthcare)
- Extends earlier pilots in Rwanda and Botswana; a parallel Penn Medicine collaboration runs through the Botswana-UPenn Partnership (Fierce Healthcare)
- OpenEvidence is already free for clinicians in the US and Europe; US clinicians logged 42 million consultations in August 2026 (Reuters)
- Daniela Amodei (Anthropic president) said market incentives alone would not make this work without philanthropic support; Daniel Nadler: ‘Access to medical knowledge shouldn’t depend on geography’
- Funding (Axios Pro, Becker’s, Sept 25): $250M at a $15B valuation, led by a16z and Byers Capital; up from $12B in January 2026 after a $250M Series D; a $20B valuation had been floated in July
- Nadler told Forbes OpenEvidence will develop oncology therapies, with a first drug in clinical trials before end-2026 (company claim)
What happened
OpenEvidence, the physician question-answering service used regularly by more than half of US doctors (Becker’s), partnered with Anthropic to extend free access to lower-resourced health systems in Africa and Asia. In the same week its valuation rose to $15B and it disclosed plans to develop its own cancer drugs.
Why it matters
It is one of the largest deployments of a frontier model for clinical decision support in low-income countries, and a sign that medical AI companies are expanding from search into drug development.
Sources
7 sources from 7 sites. Numbers match the chips in the text.
7 sources: 7 press
Press
- Reuters via Business Standard: Anthropic, OpenEvidence collaborate to bring medical AI worldwidebusiness-standard.com, press
- Reuters via Express Tribune: Anthropic, OpenEvidence partner to bring medical AI worldwidetribune.com.pk, press
- Fierce Healthcare: OpenEvidence partners with Anthropic, Penn Medicine to expand physician access to AI across Africa and Asiafiercehealthcare.com, press
- TNW: Anthropic and OpenEvidence to offer free medical AI to doctors in about 100 countriesthenextweb.com, press
- Axios Pro: OpenEvidence reportedly raises $250M at $15B valuationaxios.com, press
- Becker’s: OpenEvidence raises $250M at $15B valuationbeckershospitalreview.com, press
- Refresh Miami: OpenEvidence hits $15B valuation as its ambitions move beyond medical searchrefreshmiami.com, press
Changes
- Filed